PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain
Anti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC anal...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/8/1452 |
| _version_ | 1797524164849958912 |
|---|---|
| author | Karmele Saez de Gordoa Ingrid Lopez Marta Marginet Berta Coloma Gerard Frigola Naiara Vega Daniel Martinez Cristina Teixido |
| author_facet | Karmele Saez de Gordoa Ingrid Lopez Marta Marginet Berta Coloma Gerard Frigola Naiara Vega Daniel Martinez Cristina Teixido |
| author_sort | Karmele Saez de Gordoa |
| collection | DOAJ |
| description | Anti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC analyzed in our center between 2017 and 2020, as well as to correlate the expression values of the same patient in different tested samples. PD-L1 immunohistochemistry (IHC) was carried out on 1279 external and internal samples: 482 negative (tumor proportion score, TPS < 1%; 37.7%), 444 low-expression (TPS 1–49%; 34.7%) and 353 high-expression (TPS ≥ 50%; 27.6%). Similar results were observed with samples from our institution (N = 816). Significant differences were observed with respect to tumor histological type (<i>p</i> = 0.004); squamous carcinoma was positive in a higher proportion of cases than other histological types. There were also differences between PD-L1 expression and the type of sample analyzed (surgical, biopsy, cytology; <i>p</i> < 0.001), with a higher frequency of negative cytology. In addition, there were cases with more than one PD-L1 determination, showing heterogeneity. Our results show strong correlation with the literature data and reveal heterogeneity between tumors and samples from the same patient, which could affect eligibility for treatment with immunotherapy. |
| first_indexed | 2024-03-10T08:53:30Z |
| format | Article |
| id | doaj.art-504f5f92963a44b0be3fef6bdff8bdc3 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T08:53:30Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-504f5f92963a44b0be3fef6bdff8bdc32023-11-22T07:20:42ZengMDPI AGDiagnostics2075-44182021-08-01118145210.3390/diagnostics11081452PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in SpainKarmele Saez de Gordoa0Ingrid Lopez1Marta Marginet2Berta Coloma3Gerard Frigola4Naiara Vega5Daniel Martinez6Cristina Teixido7Thoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainThoracic Oncology Unit, Department of Pathology, Hospital Clínic of Barcelona, 08036 Barcelona, SpainAnti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC analyzed in our center between 2017 and 2020, as well as to correlate the expression values of the same patient in different tested samples. PD-L1 immunohistochemistry (IHC) was carried out on 1279 external and internal samples: 482 negative (tumor proportion score, TPS < 1%; 37.7%), 444 low-expression (TPS 1–49%; 34.7%) and 353 high-expression (TPS ≥ 50%; 27.6%). Similar results were observed with samples from our institution (N = 816). Significant differences were observed with respect to tumor histological type (<i>p</i> = 0.004); squamous carcinoma was positive in a higher proportion of cases than other histological types. There were also differences between PD-L1 expression and the type of sample analyzed (surgical, biopsy, cytology; <i>p</i> < 0.001), with a higher frequency of negative cytology. In addition, there were cases with more than one PD-L1 determination, showing heterogeneity. Our results show strong correlation with the literature data and reveal heterogeneity between tumors and samples from the same patient, which could affect eligibility for treatment with immunotherapy.https://www.mdpi.com/2075-4418/11/8/1452PD-L1immunotherapyimmunohistochemistrylung cancerNSCLC |
| spellingShingle | Karmele Saez de Gordoa Ingrid Lopez Marta Marginet Berta Coloma Gerard Frigola Naiara Vega Daniel Martinez Cristina Teixido PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain Diagnostics PD-L1 immunotherapy immunohistochemistry lung cancer NSCLC |
| title | PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain |
| title_full | PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain |
| title_fullStr | PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain |
| title_full_unstemmed | PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain |
| title_short | PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain |
| title_sort | pd l1 expression in non small cell lung cancer data from a referral center in spain |
| topic | PD-L1 immunotherapy immunohistochemistry lung cancer NSCLC |
| url | https://www.mdpi.com/2075-4418/11/8/1452 |
| work_keys_str_mv | AT karmelesaezdegordoa pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT ingridlopez pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT martamarginet pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT bertacoloma pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT gerardfrigola pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT naiaravega pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT danielmartinez pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain AT cristinateixido pdl1expressioninnonsmallcelllungcancerdatafromareferralcenterinspain |